Second primary melanomas on treatment with vemurafenib

British Journal of Dermatology

Volumn 168, Issue 4, 2013, Pages 887-888

  Dalle, S ^a   Poulalhon, N ^a   Debarbieux, S ^a   Thomas, L ^a,b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; VEMURAFENIB;

EPILUMINESCENCE MICROSCOPY; FOLLOW UP; HUMAN; LETTER; MELANOMA; PRIORITY JOURNAL; SECOND PRIMARY MELANOMA; WILD TYPE;

DRUG ERUPTIONS; HUMANS; INDOLES; MELANOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84875431187     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12093     Document Type: Letter

References (5)

1. Sinha R, Edmonds K, Newton-Bishop JA, et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012; 167: 987-94.
2. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
3. Dalle S, Poulalhon N, Thomas L,. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 365: 1448-9; author reply 1450.
4. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; 30: 2375-83.
5. Vestergaard ME, Macaskill P, Holt PE, et al. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008; 159: 669-76.